We are live on ! Find out more
NMTC icon

NeuroOne Medical Technologies

18 hedge funds and large institutions have $2.19M invested in NeuroOne Medical Technologies in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

600% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 1

0% more funds holding

Funds holding: 18 → 18 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 4

1.15% less ownership

Funds ownership: 10.98% → 9.83% (-1.2%)

42% less capital inflows, than outflows

Capital inflows: $162K | Capital outflows: $281K

Holders
18
Holders Change
–
Holders Change %
0%
% of All Funds
0.26%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
4
Increased
7
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

NMTC Hedge Fund Activity: Q2 2024 in Review

18 of the 6,945 institutional investors tracked by Wall St. Rank reported a position in NeuroOne Medical Technologies (NMTC) for Q2 2024, worth a combined $2.19M — down 36% from $3.42M a quarter earlier.

Fund positioning in NMTC was balanced in Q2 2024: 4 funds opened new positions, 4 closed out, 7 added to existing stakes and 1 trimmed.

The largest buyer was UBS Group, adding an estimated $59.9K. The largest seller was Nantahala Capital Management, cutting an estimated $260K.

  • 18 institutional investors held NeuroOne Medical Technologies (NMTC) as of Q2 2024, unchanged from Q1 2024.
  • Funds reported $2.19M of NeuroOne Medical Technologies stock for Q2 2024, down 36% quarter-over-quarter.
  • 4 funds opened new NeuroOne Medical Technologies positions in Q2 2024 and 4 closed out, a net change of 0 holders.
  • The largest NeuroOne Medical Technologies buyer in Q2 2024 was UBS Group, an estimated $59.9K added.
  • The largest NeuroOne Medical Technologies seller in Q2 2024 was Nantahala Capital Management, an estimated $260K sold.

Based on aggregated 13F filings for Q2 2024.